RELA and metabolic disease: Indeed several recent studies confirmed that SIRT1-mediated deacetylation of p65/RelA inhibited the NF-κB signaling and the activation of SIRT1 could alleviate a multitude of NF-κB-driven inflammatory and metabolic disorders [40], [41].